p-Hydroxybenzoic Acid p-HBA Engineering Service

Muconic Acid (cis,cis-Muconic Acid) is a high-value bio-monomer that serves as a key Nylon 6 Monomer precursor, offering a sustainable route to produce Caprolactam and adipic acid. The traditional method is unsustainable: Chemical synthesis from petrochemical Benzene is energy-intensive and toxic. This petrochemical dependence limits sustainability and increases environmental impact.

CD Biosynsis offers a complete biocatalytic platform: Metabolic Engineering: Engineer E. coli to shunt carbon flux from Shikimate or Tyrosine to p-HBA. This effectively converts renewable sugar feedstock. We then apply Overexpression of 4-Hydroxybenzoate Synthase ubiC. This targeted engineering strategy delivers high-titer, bio-based p-HBA, offering a superior alternative to energy-intensive chemical methods.

Pain Points

Traditional Caprolactam synthesis via Benzene or Cyclohexane routes is plagued by these issues:

• Toxic Feedstock: Chemical synthesis begins with Benzene a known carcinogen derived from petrochemicals, posing significant handling and environmental risks.
• Energy Intensive: The chemical conversion process e.g. catalytic oxidation and Beckmann rearrangement requires extreme temperatures and pressures, resulting in high utility costs.
• Inefficient Bioconversion: Biological routes to Muconic Acid often suffer from low titer and yield due to bottlenecks in the Shikimate pathway and product toxicity.
• Downstream Purification Complexity: The resulting muconic acid must be converted to Adipic Acid or Caprolactam, which requires expensive and harsh catalytic hydrogenation steps.

A bio-based platform using Muconic Acid offers a cleaner, renewable alternative.

Solutions

CD Biosynsis designs a Shikimate-to-Muconic Acid platform for Nylon monomer synthesis:

Shikimate or Tyrosine Pathway Shunting

           

We engineer E. coli to overcome Shikimate pathway regulation and knockout competing pathways to efficiently divert flux to p-HBA precursors.

Overexpression of 4-Hydroxybenzoate Synthase ubiC

We overexpress the final conversion enzyme ubiC to ensure rapid and highly efficient conversion of precursors into p-HBA.

Cofactor and Energy Balance Optimization

We optimize NADH or NADPH supply and ATP availability to support the high demands of the engineered biosynthetic pathway.

In Situ Product Removal ISPR Strategy

We design and implement ISPR methods e.g. resin adsorption to continuously remove p-HBA from the broth, reducing toxicity and boosting titer.

Our solution ensures a sustainable, high-titer production of p-HBA for advanced polymer applications.

Advantages

Our p-Hydroxybenzoic Acid p-HBA engineering service offers these core benefits:

Non-Toxic, Renewable Feedstock

Production uses renewable sugars e.g. glucose instead of fossil-fuel-derived Phenol, reducing carbon footprint.

High Titer via Flux Control

Targeted Shikimate pathway engineering maximizes carbon flow and overcomes native regulation, achieving commercially relevant titers.

Reduced Downstream Costs

ISPR integration allows for continuous removal of the product, simplifying recovery and reducing downstream purification expenses.

Low Energy Bioprocess

Fermentation runs at near-ambient conditions, eliminating the need for the high pressure and temperature of chemical Kolbe-Schmitt synthesis.

Superior Bio-Purity

Enzymatic specificity e.g. ubiC overexpression ensures high purity and minimal byproduct formation, essential for polymer applications.

We provide a sustainable, cost-effective, and high-performance p-HBA production platform.

Process

Our p-Hydroxybenzoic Acid p-HBA engineering service follows a rigorous, multi-stage research workflow:

• Pathway Deregulation and Shunting: Engineer feedback-resistant DAHP Synthase and knockout Tyrosine degradation pathways to maximize precursor availability.
• Final Conversion Optimization: Clone and tune the expression of 4-Hydroxybenzoate Synthase ubiC to sustain high flux conversion.
• Tolerance and ISPR Integration: Engineer cell membrane modifications for enhanced tolerance and implement resin adsorption ISPR to reduce toxicity.
• Host Metabolic Refinement: Optimize cofactor e.g. NADH and ATP availability by modifying the TCA cycle and Glycolysis flux.
• Process Validation: Perform high-density fed-batch fermentation and validate p-HBA titer, yield, and purity for commercial use.

Technical communication is maintained throughout the process, focusing on timely feedback regarding yield and product stability attributes.

Explore the potential for a stable, high-yield p-Hydroxybenzoic Acid p-HBA supply. CD Biosynsis provides customized strain and process engineering solutions:

• Detailed p-HBA Titer, Yield, and ISPR Efficiency Reports g/L, percent theoretical, adsorption rate.
• Consultation on Liquid Crystal Polymer LCP monomer specifications to ensure purity compliance.
• Experimental reports include complete raw data on Shikimate pathway flux analysis, enzyme activities, and product toxicity assays.